Enhancing Medication-based Analgesia in Humans

• Status: Completed
• Trial end date: 2020-03-23
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (Dilaudid).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johns Hopkins University

Criteria

Inclusion Criteria:

• Not pregnant or breast feeding

• Medically cleared to take blinded study medications

• Willing to comply with study protocol

Exclusion Criteria:

• Not experiencing and/or being treated for current pain

• Lack of significant medical or psychiatric illness that would interfere with study participation or informed consent

• Known allergy to the blinded study medications